{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:51:49Z","timestamp":1784303509302,"version":"3.55.0"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s146506","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T01:06:41Z","timestamp":1507770401000},"page":"2957-2968","source":"Crossref","is-referenced-by-count":21,"title":["Clinical and pharmacological hallmarks of rifapentine’s use in diabetes patients with active and latent tuberculosis: do we know enough?"],"prefix":"10.2147","volume":"Volume 11","author":[{"given":"Chunlan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,10]]},"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=38831","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=38831","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T01:06:42Z","timestamp":1507770402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/clinical-and-pharmacological-hallmarks-of-rifapentiners-use-in-diabete-peer-reviewed-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/dddt.s146506","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}